💰 Cannabis Capital Picked Survival Over Growth

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today's edition is sponsored by The Deep View and The Code. Their support keeps these briefings free and focused on what actually matters.

This morning's edition tracks an industry running on borrowed time and borrowed money. Debt now accounts for 91 percent of cannabis capital raised this year, nearly all of it spent staying alive rather than growing. The companies that bet on scale are restructuring. The states that bet on control are watching brewers, lawyers, and wholesalers fight back. And the federal government keeps sending mixed signals: rescheduling with one hand, tightening the hemp market with the other, and dropping military marijuana waivers on 4/20 because even the Army knows the country moved.

💰 Cannabis capital in survival mode
🏚️ Cannabist's restructuring maps the next wave
🪖 The Army dropped its marijuana waiver

Cannabis capital has not disappeared. It has shifted into preservation mode. Industry data show debt made up roughly 91 percent of U.S. cannabis capital raised in 2025, with much of that money used to refinance existing obligations rather than fund expansion. None of this should surprise anyone who has watched the federal government's relationship with this industry over the past decade. Institutional investors are inherently cautious. They watched the Biden administration float rescheduling without delivering it. They watched SAFE Banking pass the House and die repeatedly in the Senate. They watched the Trump administration promise reform at a signing ceremony and then attach a hemp provision to a spending bill that could collapse the category. Capital does not respond to promises. It responds to certainty, and this industry has offered almost none. As a result, debt remains expensive, licensing structures continue to limit ownership and consolidation, and smaller operators face a funding environment built for survival rather than growth. The market keeps moving, with far less room for new entrants or second chances. (MJBizDaily)

The Cannabist Company's planned Chapter 15 case is a sign of where the market goes when debt pressure stops being manageable. The company, formerly Columbia Care, has launched Canadian restructuring proceedings under the CCAA, is seeking U.S. recognition through a Delaware bankruptcy court, and is already executing asset sales: Ohio operations to Holistic Industries, Delaware assets to Parma Holdco for $16.5 million, and a non-binding MOU covering divestitures in Illinois, New Jersey, Colorado, Massachusetts, Maryland, and West Virginia. The company plans to wind down operations in states not included in any sale, most notably New York and Pennsylvania. More than 60 percent of its secured noteholders have agreed to support the process. Restructuring is also a sign of market maturity. As cannabis businesses scale and market conditions shift, the ones that overextended will reorganize, and the ones with capital and discipline will buy what they can no longer hold. Court-supervised asset sales and creditor leverage now sit closer to the center of this story than earnings calls or capital raises. The question worth watching is where those licenses land next. (Law360)

🪖 The U.S. Army will no longer require recruits to obtain a waiver for a single conviction for marijuana possession or drug paraphernalia. One of the country's most rule-bound institutions is conceding that old cannabis disqualifiers no longer match the recruiting market or the country it serves. The regulation still prohibits in-service use and still requires waivers for multiple offenses. And when does it take effect? 4/20, of course. (People)

Virginia's adult-use timeline keeps running into a simple constraint: cultivation cannot be accelerated by statute. A proposed 2027 launch would likely leave the state's five pharmaceutical processors with a practical head start while independent cultivators are still building facilities and completing early harvest cycles. That creates a structural imbalance from day one. Virginia should be planning now for where initial inventory comes from, including allowing existing licensees to build that early supply base. The harder question is ensuring that the rollout does not hollow out the medical channel in the process. Patients depend on both the volume and variety of products that the current program provides. An adult-use launch that cannibalizes medical supply before independent cultivators are operational is a policy failure, not a market correction. Virginia can move forward on schedule, but the market it creates will reflect who already has product, not who has been promised a license. (Cardinal News)

Ohio's new rules are already redirecting where cannabinoid commerce happens. With intoxicating hemp products pushed out of general retail as of March 20th, dispensaries are seeing immediate traffic gains from customers who previously bought through gas stations and vape shops. The fuller picture is worth tracking. The legislature passed SB 56 with a carveout for hemp-derived THC beverages up to 5 milligrams, allowing sales through the end of 2026. Governor DeWine line-item vetoed that provision. The industry responded on multiple fronts: Fifty West Brewing, Urban Artifact, Cycling Frog, and Sarene Craft Beer Distributors filed a lawsuit in the Ohio Supreme Court challenging the veto as unconstitutional executive overreach. A referendum effort failed to gather enough signatures. And a coalition of breweries including Rhinegeist, Great Lakes, Saucy Brew Works, MadTree, and Jackie O's hit 10,000 supporters through the SaveOhioBevs campaign, urging House Speaker Huffman and Senate President McColley to schedule an override vote. SB 56 passed the Senate with a veto-proof majority but fell short in the House. The industry is mobilizing both its supply chain and its consumers. Whether that pressure produces an override depends on whether legislative leadership sees this as a fight worth having. (Brewbound)

The Wine & Spirits Wholesalers of America launched an educational microsite this week arguing that intoxicating hemp beverages should be regulated consistent with alcohol, leveraging the three-tier distribution system that wholesalers already control. WSWA has also backed the Hemp Planting Predictability Act, which would push the federal compliance cliff from November 2026 to 2028. WSWA president Francis Creighton framed the stakes plainly: without congressional action, hemp beverages face removal from licensed retail shelves while remaining available through unregulated channels. WSWA has been a steadfast ally for the hemp beverage sector, and their institutional clout in statehouses and in Washington is real. They have extended that clout to hemp brands in ways that carry genuine value. The question is whether it will be enough to take on the titans of beverage alcohol who have drawn a clear line in the sand. Those companies are not opposing the category because they dislike it. They want it for themselves. Hemp brands may need WSWA's muscle right now, but they should understand the difference between being protected and being absorbed. (Food & Beverage Magazine)

🌍 Germany's medical cannabis import boom continues to rewrite the scale assumptions for European markets. Imports surged from roughly 32 tons in 2023 to an estimated 192 tons in 2025, with the BfArM raising its import cap after the original 122-ton ceiling was exhausted. Canada remains the dominant supplier, followed by Portugal and Denmark. The continent still moves slower than many investors want, and proposed amendments to the Medical Cannabis Act could restrict telemedicine prescribing and mail-order dispensing. But the center of gravity in medical trade and international operator attention is shifting toward Europe. Ignore it at your own risk. (Cannabis & Tech Today)

Jushi Holdings announced the first settlement in its Pennsylvania litigation campaign this week. The company's subsidiaries settled with Revelry Supply, Inc., resolving claims filed in the Court of Common Pleas of Philadelphia County as part of a broader action targeting roughly a dozen defendants over the sale of unregulated intoxicating hemp-derived THC products. The original suit, filed in August 2025, alleged that wholesalers and smoke shops were selling products that exceeded Pennsylvania's THC limits and bypassed the testing, licensing, and safety requirements that Jushi's 18 Beyond Hello dispensaries must follow. A Philadelphia Inquirer investigation last July found that nine out of ten hemp products tested from southeastern Pennsylvania exceeded the legal THC threshold. A settlement like this is its own kind of market signal. Licensed operators are not just filing complaints. They are litigating, managing cases through the system, and resolving them on terms that let them keep pursuing the rest. That is private enforcement maturing. When companies hire lawyers to define the market boundary, it usually means the old policy lines are no longer containing the dispute. (MJBizDaily)

The federal hemp coverage pilot is starting to look less theoretical and more like a contest over institutional access. Cornbread Hemp, a Louisville-based USDA organic CBD company, has secured an exclusive supplier contract with Alliant Purchasing, a national Group Purchasing Organization whose member network serves 68,000 healthcare provider locations across Accountable Care Organizations participating in the CMMI program. Under the pilot, participating ACOs in the ACO REACH, Enhancing Oncology, and LEAD models may offer eligible Medicare beneficiaries up to $500 per year in hemp products, furnished by a qualified physician as part of a documented clinical consultation. The program launches in April. Cornbread enters with more than a supplier contract. Co-founder Jim Higdon was elected chairman of the U.S. Hemp Roundtable for 2026, giving the company both institutional purchasing access and a seat at the federal policy table. Once clinical gatekeepers, purchasing networks, and documentation standards come into play, the brands built for institutional scrutiny can pull away from the rest of the field very quickly. Worth watching: whether other brands emerge as suppliers, and whether companies staring at the November compliance cliff start treating the pilot as a product pivot rather than a niche play. (BusinessWire)

A federal judge is allowing the latest challenge to New York's cannabis licensing system to move forward after the Second Circuit already found parts of the state's priority framework vulnerable under the dormant Commerce Clause. In Variscite NY Four v. New York State Cannabis Control Board, the Second Circuit ruled last August that New York's "extra priority" for license applicants with in-state cannabis convictions functioned as a proxy for residency and amounted to economic protectionism. The Ninth Circuit split from that reasoning in January, holding that the dormant Commerce Clause does not apply to cannabis licensing at all because the market remains federally illegal. That circuit split means this question may be heading to the Supreme Court, and New York's program sits squarely in the crosshairs. The policy instinct behind New York's approach was understandable. The structure was harder to defend. We have covered the recent leadership changes at the Office of Cannabis Management and the regulatory recalibrations that followed. There are real signs of stabilization: new license approvals are moving, cultivation canopy is expanding, and the state surpassed $2 billion in adult-use sales. The hope is that the newfound institutional stability translates into a market that finally gets operational traction. New York still has the scale and the demand. What it needs now is the consistency to let operators actually build. (Law360)

Georgia's medical cannabis overhaul may do more than improve treatment options. By removing the old THC cap, allowing vaporized products for adult patients, and broadening eligibility, the state is setting up enrollment growth that could trigger additional retail permits under current law. Georgia has spent years operating a program too narrow to build meaningful patient demand and too tight to create commercial momentum. If Gov. Brian Kemp signs the bill, the state may finally start behaving like it wants a medical market that can function. Even so, this remains one of the most restrictive programs in the country, and progress here is relative to a very low baseline. (MJBizDaily)

California is still dealing with the environmental fallout of illicit cannabis cultivation, and the scale is larger than most policy debates acknowledge. Thousands of abandoned grow sites remain scattered across public lands, leaking pesticides, fertilizers, and other contaminants into fragile ecosystems. The federal government has not dedicated funding to address the problem, leaving state agencies to carry the burden while the backlog grows. This should resonate with anyone who remembers the original Cole Memo. In 2013, the Justice Department laid out eight federal enforcement priorities that would guide its approach to states legalizing cannabis. One of them was specifically preventing the growing of marijuana on public lands and the environmental dangers that came with it. That concern was central to the federal government's conditional tolerance of state legalization. Over a decade later, the damage the Cole Memo tried to prevent is exactly what California is left cleaning up, largely without federal help. (Trinity Journal)

🏜️ Arizona lawmakers are advancing a bill that would let excessive marijuana smoke or odor be treated as a public nuisance even when the underlying use is lawful. This is NIMBYism dressed in statutory language, advanced in a state where voters already approved legalization. These battles often begin with nuisance standards, local enforcement hooks, and rules that fall hardest on renters, patients, and anyone without total control over where they consume. (Marijuana Moment)

🌐 A House proposal aimed at expanding deportation authority could capture conduct that remains illegal at the federal level even as states move in another direction. The contradiction is hard to miss: the same administration pursuing rescheduling is expanding the deportation apparatus that treats cannabis activity as a trigger for removal. (Marijuana Moment)

🚨 South Dakota may be showing the difference between passing a rule and making a market obey it. Local reporting suggests illegal hemp sales are continuing despite state restrictions, even as prosecutors publicly reiterate that smokable hemp products are prohibited. Bans often look cleaner on paper than they do in storefronts. When products remain easy to find after lawmakers say they are off limits, the real test becomes whether the state has the appetite and capacity to enforce its own line consistently. (KELOLAND)

You're spending 40 hours a week writing code that AI could do in 10.

While you're grinding through pull requests, 200k+ engineers at OpenAI, Google & Meta are using AI to ship faster.

How?

The Code newsletter teaches them exactly which AI tools to use and how to use them.

Here's what you get:

Sign up and get access to the Ultimate Claude code guide to ship 5X faster.

Join 200K+ engineers

Gavin Newsom is using his memoir rollout to remind voters that he backed California legalization, and that matters because he is plainly speaking to a national audience. For a likely 2028 contender, cannabis now looks less like a liability than a piece of cultural shorthand. Claiming credit for legalization after the fact is easy politics. The harder test for national candidates is whether any of them will treat federal cannabis reform as more than lifestyle branding once real governing choices are on the table. Newsom still has an opportunity to lead here if he wants to. California's sheer market size gives him a platform to go bold. He could push to regulate cannabinoids rather than plants, creating a framework that the federal government could actually learn from. That would be governing. The memoir is just positioning. (Marijuana Moment)

Missouri Attorney General Catherine Hanaway announced a statewide investigation this week into retailers selling intoxicating hemp-derived products, issuing Civil Investigative Demands to five smoke shops across the state. The targeted products include Delta-8, Delta-10, THC-P, HHC, THC-O, and other chemically converted compounds. The CIDs require detailed disclosure on manufacturing processes, chemical composition, consumer representations, contaminant testing, and adverse reaction reports. This is the second wave of AG enforcement. Earlier this year, under former AG Andrew Bailey, the office sent 18 cease-and-desist letters to companies selling THCA flower, relying on the Missouri Merchandising Practices Act and DEA interpretations that count THCA toward total THC. Cannabis attorneys have questioned whether that legal theory holds without explicit statutory authority: Missouri lawmakers have failed to pass intoxicating hemp legislation three years running. Labeling and contamination standards are becoming one of the sharpest tools states have for policing the blurry edge between regulated marijuana and loosely sold intoxicating goods. Product integrity has become an enforcement lever in its own right. (KSDK)